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Abstract
Background: Insulin plays diverse roles in the brain. Although insulin produced by pancreatic β-cells that crosses
the blood–brain barrier is a major source of brain insulin, recent studies suggest that insulin is also produced locally
within the brain. However, the mechanisms underlying the production of brain-derived insulin (BDI) are not yet
known.
Results: Here, we examined the effect of Wnt3a on BDI production in a hypothalamic cell line and hypothalamic
tissue. In N39 hypothalamic cells, Wnt3a treatment significantly increased the expression of the Ins2 gene, which
encodes the insulin isoform predominant in the mouse brain, by activating Wnt/β-catenin signaling. The concentration
of insulin was higher in culture medium of Wnt3a-treated cells than in that of untreated cells. Interestingly, neurogenic
differentiation 1 (NeuroD1), a target of Wnt/β-catenin signaling and one of transcription factors for insulin, was also
induced by Wnt3a treatment in a time- and dose-dependent manner. In addition, the treatment of BIO, a GSK3
inhibitor, also increased the expression of Ins2 and NeuroD1. Knockdown of NeuroD1 by lentiviral shRNAs reduced
the basal expression of Ins2 and suppressed Wnt3a-induced Ins2 expression. To confirm the Wnt3a-induced increase in
Ins2 expression in vivo, Wnt3a was injected into the hypothalamus of mice. Wnt3a increased the expression of NeuroD1
and Ins2 in the hypothalamus in a manner similar to that observed in vitro.
Conclusion: Taken together, these results suggest that BDI production is regulated by the Wnt/β-catenin/NeuroD1
pathway in the hypothalamus. Our findings will help to unravel the regulation of BDI production in the hypothalamus.
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Background
Recognition of the importance of insulin action in the
brain has grown in many aspects such as energy balance,
glucose homeostasis, neuronal survival, synapse forma-
tion, and cognition [1–4]. In particular, studies on the
relationship between metabolic and neurodegenerative
diseases emphasized the role of insulin signaling in the
brain [5–10]. However, the source of insulin in the brain
has not been fully investigated.
Insulin produced in pancreatic β-cells is a major source
of plasma insulin. Insulin produced by the pancreas is
supplied to the brain from the blood circulation through
the blood–brain barrier [11, 12], since insulin can be
transported across this barrier [13]. However, not all insu-
lin in the brain comes from the pancreas, because insulin
can also be produced in the brain [14, 15]. Insulin mRNA
is detected in various regions of the brain both during
development and in adults. Rodents have two non-allelic
insulin genes, Ins1 and Ins2 [14, 15]. In the pancreas, both
genes are expressed, with Ins2 expressed at a higher level
[16]. Interestingly, Ins1 mRNA is not detected in the
brain. Instead, Ins2 mRNA is found in limbic and olfactory
regions, hippocampus, and hypothalamus [6, 17–22].
Nevertheless, it is difficult to detect Ins2 mRNA in the
brain because of its quite low expression level. Using
single-cell digital PCR, one research group found that the
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neurogliaform cells in the cerebral cortex express Ins2
mRNA [23]. To verify the production of insulin in the
brain, brain was stained with antibodies against connect-
ing peptide (c-peptide), byproduct of proinsulin process-
ing. C-peptide–positive signal was found in the central
nervous system, and the pattern of c-peptide staining
showed correlation with that of Ins2 expression [24, 25].
However, the mechanisms of local production of insulin
in the brain, which is called brain-derived insulin (BDI),
and its roles remain unclear.
Wnt signaling is involved in brain development [26–28].
Wnt proteins are a diverse family of secreted glycopro-
teins that act as ligands for receptor-mediated signaling
pathways [29]. The three well-characterized Wnt sig-
naling pathways are the canonical Wnt pathway, the
non-canonical planar cell polarity pathway, and the
non-canonical Wnt/calcium pathway.
The canonical Wnt signaling regulates the expression
of insulin in pancreatic β-cells and the development of
the pancreas [30–35]. Without Wnt ligands, β-catenin,
which enhances the expression of many genes in the nu-
cleus, is degraded by the β-catenin destruction complex
[36]. Glycogen synthase kinase 3 (GSK3), a key compo-
nent of the β-catenin destruction complex, phosphory-
lates β-catenin at Ser33, Ser37, and Thr41, leading to its
degradation by the proteasome [37]. When Wnt ligands
bind to Frizzled (Fz) receptor and its coreceptor, low
density lipoprotein receptor–related protein (LRP), the
β-catenin destruction complex is disrupted by GSK3
inactivation [38]. Consequently, β-catenin accumulates in
the cytosol and translocates into the nucleus to enhance
the expression of many target genes [39].
The activity of the canonical Wnt signaling is also
observed in the adult mice hypothalamus [40, 41]. Wnt-
responsive cells are abundant in the paraventricular and
arcuate nuclei of the hypothalamus [42, 43]. In the mouse
models of metabolic diseases such as diet-induced obese
(DIO) mouse model and leptin-deficient (ob/ob) mouse
model, hypothalamic Wnt signaling is disrupted [44].
GSK3 is increased in the hypothalamus of DIO mice, and
a GSK3 inhibitor acutely improves glucose metabolism in
these mice [44]. In addition, the phosphorylated (active)
form of LRP is down-regulated in ob/ob mice [45]. Down-
regulated Wnt signaling is reinstated by leptin treatment
[45]. These reports suggest that Wnt signaling is necessary
for glucose homeostasis in the hypothalamus. However,
the specific mechanism how Wnt signaling modulates me-
tabolism in the hypothalamus has not yet been revealed.
Insulin signaling plays many roles in the brain [46],
however, the mechanisms underlying the expression of
insulin in the brain have not been discovered yet. In this
study, we examined how Wnt signaling regulates the
production of insulin in the hypothalamus. The results
of our research will help to reveal the mechanisms
underlying the regulation of BDI production in the
hypothalamus.
Results
Wnt3a increases the levels of Ins2 mRNA and protein in
N39 cells
We used the immortalized mouse hypothalamic neuronal
cell line N39 (mHypoE-39) to investigate the mechanism
of BDI production, because N39 cells express Ins2 [14].
Consistent with the previous findings [14], Ins2 mRNA
but not Ins1 mRNA was detected by quantitative real-
time PCR (qRT-PCR) in N39 cells (data not shown).
Wnt3a increases insulin expression in pancreatic β-cells
and neuronal progenitor cells (derived from adult hippo-
campus or the olfactory bulb) via Wnt/β-catenin signaling
[35, 47]. Therefore, we tested whether Wnt3a can induce
insulin production in N39 cells.
N39 cells were treated with Wnt3a (25 or 100 ng/mL)
for 6, 12, or 24 h. After Wnt3a treatment for 6 h, the
Ins2 mRNA level increased significantly (by 4.1-fold at
25 ng/mL and 3.5-fold at 100 ng/mL Wnt3a; Fig. 1a),
although this increase was not dose-dependent. After
12 h, Wnt3a increased the Ins2 mRNA level by 3.9-fold
at 25 ng/mL and 4.7-fold at 100 ng/mL. After 24 h, the
Ins2 mRNA level was increased by 5.4-fold at 25 ng/mL
and 6.8-fold at 100 ng/mL of Wnt3a compared to vehicle-
treated cells. Thus, the Ins2 mRNA levels were significantly
increased in Wnt3a-treated N39 cells in a time-dependent
manner at 12 and 24 h.
To confirm the expression of insulin, we checked its
protein level using immunofluorescence analysis with
an antibody against proinsulin and found stronger
proinsulin-positive signals in N39 cells treated with
Wnt3a (100 ng/mL) for 24 h than in vehicle-treated
cells (Fig. 1b).
To further verify the production of insulin in Wnt3a-
treated N39 cells, culture medium was collected after
Wnt3a treatment for 24 h, concentrated, and the concen-
tration of immuno-reactive insulin was measured with
ELISA. The concentration of insulin in culture medium
was significantly increased (by 17.4 %) in cells treated with
Wnt3a (100 ng/mL) as compared to vehicle-treated cells
(Fig. 1c).
Taken together, our results indicate that Wnt3a in-
creases the levels of insulin mRNA and protein in N39
cells. Furthermore, Wnt3a also increases secretion of
insulin from N39 cells.
Wnt3a induces insulin production in N39 cells through
the canonical Wnt/β-catenin signaling
In the canonical Wnt signaling, Wnt ligands bind to
Fz receptor and LRP, and this binding results in the
stabilization, accumulation, and nuclear translocation
of β-catenin [48, 49]. To determine whether Wnt3a
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induced Ins2 through the canonical Wnt signaling, we
measured the level of β-catenin in Wnt3a-treated N39
cells.
Immunoblot analysis (Fig. 2a-c) showed that Wnt3a
strongly stabilized β-catenin in a dose-dependent man-
ner, as shown by a significant increase in the levels of
active β-catenin, in which the Ser33, Ser37, and Thr41
residues are dephosphorylated. Consequently, total β-
catenin also accumulated in a dose-dependent manner.
Consistent with the immunoblotting data, immunofluor-
escence analysis showed that Wnt3a treatment resulted
in the accumulation of active β-catenin (Fig. 2d). Fur-
thermore, active β-catenin was clearly co-localized with
Hoechst 33342, a nuclear marker, in Wnt3a-treated N39
cells.
To ascertain the role of GSK3 in insulin production
stimulated by Wnt3a treatment in N39 cells, we treated
them with 6-bromoindirubin-3′-oxime (BIO), a specific
Fig. 1 Wnt3a upregulates insulin synthesis and secretion from N39, a hypothalamic neuronal cell line. a N39 cells were treated with vehicle (PBS)
or Wnt3a (25 or 100 ng/mL) for 6, 12, and 24 h, and the levels of Ins2 mRNA were measured by qRT-PCR and normalized to the levels of GAPDH
mRNA (n= 23). b N39 cells were treated with vehicle or Wnt3a (100 ng/mL) for 24 h, and the induction of insulin was examined by immunofluorescence
analysis with an antibody against proinsulin. Nuclei were stained with Hoechst 33342 dye. Scale bar, 20 μm. c Culture media were collected for 24 h after
treatment with vehicle or Wnt3a (100 ng/mL), concentrated in Vivaspin columns, and insulin concentrations were measured by ELISA (n= 6). Data are
means + SEM. *p< 0.05, **p < 0.01, ***p < 0.001 compared with vehicle control at each time point
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Fig. 2 (See legend on next page.)
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GSK3 inhibitor. BIO inhibits GSK3 by interacting with
its ATP binding pocket, leading to activation of the ca-
nonical Wnt signaling in human and mouse embryonic
stem cells [50, 51]. BIO treatment increased the level of
Ins2 mRNA by 2-fold after treatment for 12 h (Fig. 2e).
As expected, the levels of both active and total β-catenin
increased by up to 2-fold after BIO treatment for 3 h,
and the increased level was maintained after BIO treat-
ment for 6 and 12 h (Fig. 2f-h). The induction of Ins2
and accumulation of β-catenin upon BIO treatment
showed trends similar to those of the effects of Wnt3a
treatment. Collectively, these data indicate that Wnt3a
increases insulin production by activating β-catenin and
it might be mediated by inactivation of GSK3.
Induction of insulin production by Wnt3a depends on
NeuroD1
To unravel the mechanism of insulin production in N39
cells, we investigated the downstream targets of Wnt/
β-catenin signaling. Among many targets of this path-
way, we tested NeuroD1, which is known as a candidate
transcription factor involved in the expression of the insu-
lin genes in the pancreas [52].
We measured the NeuroD1 mRNA level at 6, 12, and
24 h in N39 cells treated with Wnt3a (25 or 100 ng/mL).
At 6 h, the level of NeuroD1 mRNA was significantly
increased in comparison with vehicle-treated N39 (by
3.7-fold at 25 ng/mL and 3.5-fold at 100 ng/mL Wnt3a;
Fig. 3a). At 12 h, NeuroD1 mRNA was upregulated by
(See figure on previous page.)
Fig. 2 Wnt3a induces the expression of Ins2 by activating Wnt/β-catenin signaling. a N39 cells were treated with vehicle or Wnt3a (25 or 100 ng/mL)
for 12 and 24 h. Active (Non-phospho) β-catenin and total β-catenin were detected using immunoblot assay. b and c The intensity of bands
shown in (a) was quantified by using the ImageJ software with normalization to GAPDH (n = 6). d N39 cells were treated with vehicle or
Wnt3a (100 ng/mL) for 24 h, and active β-catenin was examined by immunofluorescence analysis; Hoechst 33342 dye was used for nuclear
staining. Scale bar, 20 μm. e N39 cells were treated with 1 μM BIO, a GSK3 inhibitor, for 12 h, and the level of Ins2 mRNA was measured by
qRT-PCR (n = 9). f N39 cells were treated with vehicle (DMSO) or 1 μM BIO for 1, 3, 6, and 12 h to observe accumulation of active β-catenin
and total β-catenin (n = 6). g and h Quantification of immunoblot data in (f) using the ImageJ software was performed with normalization to
GAPDH. Data are means + SEM. **p < 0.01, ***p < 0.001 compared with vehicle treatment
Fig. 3 Wnt3a increases the expression of NeuroD1 by activating Wnt/β-catenin signaling in N39 cells. a NeuroD1 mRNA levels were quantified
using qRT-PCR after vehicle or Wnt3a (25 or 100 ng/mL) treatment for 6, 12, and 24 h (n = 23). b NeuroD1 protein levels were measured by
immunoblot assay after vehicle or Wnt3a (20 or 100 ng/mL) treatment for 12 and 24 h. c The intensity of bands shown in (b) was quantified
by using ImageJ with normalization to GAPDH (n = 6). d After treatment with vehicle or Wnt3a (100 ng/mL) for 24 h, NeuroD1 was examined
using the immunofluorescence assay; the nuclei were stained with Hoechst 33342 dye. Scale bar, 20 μm. e The level of NeuroD1 mRNA was
determined by qRT-PCR 12 h after treatment with 1 μM BIO (n = 9). f Cells were treated with 1 μM BIO, and the level of NeuroD1 was measured by
immunoblot assay after treatment for 1, 3, 6, and 12 h. g The intensity of NeuroD1 bands in (f) was quantified using the ImageJ software
and normalized to GAPDH (n = 6). Data are means + SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared with vehicle treatment
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3.9-fold at 25 ng/mL and 5.1-fold at 100 ng/mL Wnt3a.
At 24 h, the effects on NeuroD1 mRNA were even more
profound (4.1-fold increase at 25 ng/mL and 8.0-fold in-
crease at 100 ng/mL Wnt3a). The induction of NeuroD1
mRNA by Wnt3a showed a pattern similar to that of
Ins2 mRNA: after Wnt3a treatment for 6 h, Ins2 and
NeuroD1 did not show dose-dependent effects, whereas
both the Ins2 and NeuroD1 mRNA levels were signifi-
cantly increased in a dose-dependent manner at 12 and
24 h. Interestingly, at 1.5 h after Wnt3a (100 ng/mL)
treatment, the mRNA level of NeuroD1 was increased
significantly whereas that of Ins2 was not increased yet
(Additional file 1: Figure S1A and S1B). To validate the
effect of Wnt3a on NeuroD1 expression, we determined
the level of the NeuroD1 protein in Wnt3a-treated N39
cells by immunoblotting (Fig. 3b and c). At 12 h, the
NeuroD1 level was significantly increased (by 3.2 fold at
25 ng/mL and 3.8 fold at 100 ng/mL Wnt3a). At 24 h,
the increase was dose-dependent (2.6 fold at 25 ng/mL
and 5.4 fold at 100 ng/mL Wnt3a).
NeuroD1 was detectable in N39 cells by immunofluor-
escence analysis (Fig. 3d). When the cells were treated
with Wnt3a (100 ng/mL) for 24 h, the intensity of the
NeuroD1-positive signal was apparently greater. Co-
localized with Hoechst 33342 demonstrated Wnt3a-
induced nuclear localization of NeuroD1. These data
demonstrate that Wnt3a increases both the expression of
NeuroD1 and its translocation into the nucleus in N39
cells.
We also treated N39 cells with BIO to determine
whether the induction of NeuroD1 is mediated by GSK3-
dependent Wnt/β-catenin signaling. The level of NeuroD1
mRNA was increased by 2-fold in cells treated with BIO
for 12 h (Fig. 3e). In a similar manner, BIO treatment for
3, 6, or 12 h significantly increased the levels of the Neu-
roD1 protein (by up to 2-fold compared to vehicle-treated
N39 cells; Fig. 3f and g). These results suggest that Wnt/
β-catenin signaling increases the expression of NeuroD1
through GSK3 inhibition.
To determine whether the induction of BDI by Wnt3a
is NeuroD1-dependent, knockdown experiments were de-
signed using a lentiviral vector system. Among 5 candidate
short-hairpin RNA (shRNA) constructs designed to target
NeuroD1, two shRNAs were chosen because of their
high knockdown efficiency and used in combination for
NeuroD1 knockdown (data not shown). Lentiviruses
expressing NeuroD1 shRNAs significantly suppressed
the expression of NeuroD1: by 80 % at the mRNA level
(Fig. 4a) and by 50 % at the protein level after 72 h
infection (Fig. 4b and c) compared to lentivirus ex-
pressing non-targeting shRNA. Interestingly, NeuroD1
knockdown reduced the expression of Ins2 by 40 % of
that in non-targeting shRNA lentivirus–infected cells
in the absence of Wnt3a, indicating that NeuroD1 is
Fig. 4 Knockdown of NeuroD1 reduces the expression of Ins2.
NeuroD1 was knocked down by infecting N39 cells with lentivirus
containing shRNA (shNeuroD1) for 72 h. a Knockdown efficiency
was determined by examining the levels of NeuroD1 mRNA using
qRT-PCR (n = 23). b The level of NeuroD1 protein was assessed by
immunoblot assay, and c the intensity of NeuroD1 bands was
quantified using the ImageJ software with normalization to GAPDH
(n = 6). d The basal expression of Ins2 was determined by qRT-PCR
after infection with shRNA lentivirus against NeuroD1 for 72 h
(n = 12). Data are means + SEM. **p < 0.01, ***p < 0.001 compared
with non-targeting shRNA lentivirus-infected cells (shNon-target)
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involved in maintaining the expression of Ins2 in the
basal state (Fig. 4d).
In addition, we treated N39 cells, in which NeuroD1
was knocked down, with Wnt3a (100 ng/mL) to examine
any changes in the induction of Ins2. As shown in Fig. 5a
and b, Wnt3a treatment resulted in the accumulation
of active and total β-catenin in cells infected with
lentiviruses expressing either non-targeting shRNA or
NeuroD1 shRNA. However, as demonstrated by using
qRT-PCR, the NeuroD1 transcript was not upregulated
by Wnt3a in N39 cells with knocked down NeuroD1,
although it was significantly increased in non-targeting
shRNA lentivirus–infected N39 cells (Fig. 5c). Further-
more, Wnt3a treatment failed to induce Ins2 in N39 cells
with knocked down NeuroD1 whereas Wnt3a significantly
increased the level of Ins2 mRNA in non-targeting shRNA
lentivirus–infected N39 cells (Fig. 5d).
Taken together, these results suggest that NeuroD1 is a
key transcription factor for Wnt3a-induced Ins2 expres-
sion through Wnt/β-catenin signaling in N39 cells.
Wnt3a administration induces the expression of Ins2 and
NeuroD1 in the hypothalamus
Many reports showed Wnt activity in the adult hypothal-
amus [40–43]. Autocrine and/or paracrine Wnt ligands
may be responsible for Wnt activity in the hypothalamus.
To test Wnt3a-induced BDI production in the hypothal-
amus in vivo, we first measured the mRNA level ofWnt3a
by qRT-PCR in the hypothalamic tissues (Fig. 6a). Al-
though the amount of Wnt3a mRNA was relatively lower
than that of Ins2, the expression of Wnt3a was detected in
the hypothalamus.
To examine the effect of Wnt3a treatment on the syn-
thesis of Ins2mRNA in hypothalamic tissue, we introduced
Wnt3a into the hypothalamus by intracerebroventricular
(icv) injection and collected hypothalamic tissues for ana-
lysis 24 h after injection. Administration of Wnt3a (4 or
20 ng) significantly increased the levels of Ins2 mRNA
(by 1.3-fold and 1.6-fold, respectively; Fig. 6b). Interest-
ingly, the levels of NeuroD1 mRNA were also upregulated
(Fig. 6c). These results indicate that Wnt3a increases the
expression of Ins2 and NeuroD1 in the hypothalamus.
Discussion
Despite accumulating evidence about BDI, the specific
mechanism of BDI production is not yet well under-
stood. In particular, hypothalamic insulin production has
not been reported. Considering that the hypothalamus
has a large number of neurosecretory cells, which produce
and secrete diverse neuropeptides involved in maintaining
homeostasis, it is plausible that BDI plays a specific role
in maintaining energy homeostasis and regulating me-
tabolism in the hypothalamus. In this study, we demon-
strated that Wnt3a increases insulin production in the
hypothalamus by activating Wnt/β-catenin signaling and
NeuroD1 induction. Inhibition of GSK3, which phosphor-
ylates β-catenin and thus promotes its degradation, leads
Fig. 5 Wnt3a-induced Ins2 upregulation is blocked by knockdown of
NeuroD1. NeuroD1 was knocked down by infecting N39 cells with
lentivirus containing shRNA for 72 h. a N39 cells were infected by
lentiviral shRNA against NeuroD1 for 48 h and then treated with
Wnt3a (100 ng/mL) for 24 h. The levels of active and total β-catenin
and NeuroD1 protein were determined by immunoblot assay. b The
intensity of NeuroD1 signal in (a) was quantified using the ImageJ
software (n = 4). The levels of NeuroD1 mRNA (c) and Ins2 mRNA (d)
were measured by qRT-PCR in N39 cells that were infected with
lentiviral non-targeting or NeuroD1 shRNA for 48 h and then treated
with Wnt3a (100 ng/mL) for 24 h (n = 9). Data are means + SEM.
***p < 0.001 compared with vehicle treatment in shNon-target.
###p < 0.001 compared with Wnt3a treatment in shNon-target.
N.S., not significant within shNeuroD1 samples
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to accumulation of β-catenin in the cytosol. Accumulated
β-catenin translocates into the nucleus, where it enhances
the expression of NeuroD1 with T-cell factor (TCF).
Synthesized NeuroD1 also moves into the nucleus
and induces insulin production (Fig. 7).
Hippocampus and olfactory regions are known as brain
regions that express insulin higher than other brain re-
gions [15, 35]. The Ins2 mRNA level is lower in the hypo-
thalamus than in the hippocampus [14, 17]. However,
insulin signaling plays important roles in controlling food
intake, glucose metabolism, and energy expenditure in the
hypothalamus [53, 54]. Nevertheless the expression level
is lower than other regions, we hypothesized that BDI syn-
thesized in the hypothalamus could regulate metabolism
by acting on the hypothalamic neurocircuits.
The activation of Wnt/β-catenin signaling enhances the
transcription of downstream genes via the formation of a
complex between active β-catenin and TCF [55]. Our results
demonstrate not only the accumulation of active and total β-
catenin (Fig. 2a-c), but also the translocation of active β-
catenin into the nucleus induced by Wnt3a in N39 cells
(Fig. 2d). Although we did not examine the activity of the
TCF complex, these results indicate activation of Wnt/β-
catenin signaling in these cells. The level of NeuroD1, a
downstream target of Wnt/β-catenin signaling, was in-
creased in Wnt3a-treated N39 cells (Fig. 3a-d). This in-
crease in NeuroD1 expression supports that Wnt3a-
induced accumulation of active β-catenin enhances the
transcription of NeuroD1 gene.
To determine whether GSK3 is involved in Wnt3a-
induced Ins2 upregulation, we treated BIO to inhibit
GSK3 (Fig. 2e-h, Fig. 3e-g). BIO treatment resulted in
accumulation of β-catenin, and increases in the ex-
pression of NeuroD1 and Ins2, suggesting that GSK3
plays a role in the upregulation of Ins2 by Wnt/β-ca-
tenin signaling. The phosphorylation of GSK3 at Ser9
residue is one of mechanisms for GSK3 inactivation
[56, 57]. However, we could not observe any changes in
the level of phospho-GSK3 (Ser9) when N39 was
treated with Wnt3a (data not shown). Therefore, it is
likely that GSK3 inhibition by Wnt3a is mediated by
not phosphorylation of Ser9 but other mechanisms in
our study.
NeuroD1 is a basic helix-loop-helix transcription factor
that plays a role in facilitating differentiation of neurons
[58, 59], and its gene is a target of Wnt/β-catenin signaling
in the brain [52, 60]. NeuroD1 also binds to the insulin pro-
moter to increase the expression [61, 62]. Although an in-
crease in Ins2 mRNA levels in Wnt3a-injected hypothalamic
tissues was smaller than that in N39 cells, the levels of both
NeuroD1 and Ins2mRNAs increased in the hypothalamus of
Wnt3a-injected mice. Taken together, it is likely that insulin
production induced by Wnt3a, which is well known to occur
in the pancreas, is conserved in the hypothalamus.
The mechanism of insulin secretion in neurons is not
yet revealed. Mechanistic studies on insulin secretion in
vivo are challenging, because it is difficult to pinpoint
Fig. 6 Wnt3a upregulates NeuroD1 and Ins2 in the mouse
hypothalamus. The basal mRNA levels of Ins2 and Wnt3a were
measured by qRT-PCR in hypothalamic tissues from C57BL/6 male
mice (n = 6−9) (a). C57BL/6 male mice received icv injections of ve-
hicle or Wnt3a (4 or 20 ng), and hypothalamic tissues were dissected
after 24 h. The mRNA levels of Ins2 (b) and NeuroD1 (c) were mea-
sured by qRT-PCR (n = 6−9). Data are means + SEM. ###p < 0.001
compared with Ins2 mRNA, ***p < 0.001 compared with
vehicle administration
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the origin of insulin in the brain; the confounding factor
is that insulin produced in the pancreas is delivered by
blood circulation to the brain in vivo. Furthermore, the
basal expression of insulin is not high enough to study
the mechanism of its secretion in in vitro systems.
Insulin-overexpressing N39 cells as an in vitro model
might be useful to investigate the mechanism of insulin
secretion in the future studies.
The neuron-specific insulin receptor knockout (NIRKO)
mice resulted in increased food intake and moderate diet-
induced obesity, demonstrating the anti-obesity role of
insulin [2]. However, insulin receptor (IR) knockout
mice specifically deleted in agouti-related peptide (AgRP)-
or pro-opiomelanocortin (POMC)-expressing neuron did
not show a significant difference in energy homeostasis,
especially food intake [63]. Moreover, deletion of IR in
steroidogenic factor 1 (SF1)-expressing neurons of the
ventromedial hypothalamus had no effect on body weight
and food intake [64]. The different phenotypes among
mice models suggest that the roles of insulin through IR
in the brain are diverse in a cell-type specific manner.
Therefore, it might be important to identify the subpopu-
lation of hypothalamic neurons that specifically express
BDI in order to investigate the role of BDI in the future
study. It would be interesting to investigate whether
Wnt3a-induced insulin production from the specific neu-
rons in the hypothalamus can regulate the food intake and
protect from obesity.
Conclusions
We demonstrate that BDI is regulated by Wnt/β-catenin
signaling in the hypothalamus. It is possible that insulin
production in the hypothalamus or other brain areas
changes in metabolic diseases. Further studies focused on
the regulation of BDI production in the disease models
with disrupted hypothalamic Wnt/β-catenin signaling will
be needed to elucidate the pathophysiological roles of
BDI.
Methods
Cell culture and treatments
Immortalized mouse hypothalamic cell line N39 (mHypoE-
39) was obtained from CELLutions Biosystems and main-
tained in Dulbecco’s modified Eagle medium (DMEM)
(Sigma) supplemented with 10 % fetal bovine serum (FBS)
(Hyclone Laboratories) and 1 % penicillin/streptomycin
(GIBCO). Lenti-X™ 293 T cell line was purchased from
Clontech and cultured in DMEM supplemented with
10 % FBS and 1 % penicillin/streptomycin. Recombinant
mouse Wnt3a (1324-WN, R&D Systems) was dissolved in
phosphate-buffered saline (PBS) containing 0.2 % BSA.
BIO (Sigma), a specific GSK3 inhibitor, was dissolved in
dimethyl sulfoxide (DMSO) at 1 mM concentration.
Animals
Animal studies were performed in accordance with the
guidelines on care and use as approved by the DGIST
Fig. 7 The proposed regulatory mechanism of insulin expression by the Wnt/β-catenin/NeuroD1 pathway in the hypothalamus. Wnt3a might
bind to LRP and Frizzed receptor to activate the canonical Wnt pathway. GSK3 phosphorylates β-catenin and induces its degradation; Wnt3a
inhibits GSK3, leading to β-catenin accumulation. Accumulated β-catenin translocates into the nucleus and enhances the expression of NeuroD1
with TCF. Up-regulated NeuroD1 also translocates into the nucleus, where it induces the production of insulin
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Institutional Animal Care and Use Committee. C57BL/6
mice were obtained from Koatech; 8-week-old males
were used for experiments. Mice were housed in groups
of 3–5 under a 12/12 h light/dark cycle (lights on from
6:00 to 18:00) in an individually ventilated cage Innorack
(Innovive).
Administration of Wnt3a and preparation of brain tissues
Wnt3a was introduced into the hypothalamus by icv
injection of 2 μL of PBS containing Wnt3a (4 or 20 ng)
into the third ventricles. Mice were euthanized with CO2
gas supplied for 3–5 min 24 h after Wnt3a administra-
tion. Brain was quickly removed, placed on ice, and the
hypothalamus was dissected using as landmarks the optic
chiasm and the mammillary bodies to depth of ~ 2 mm
[65]. Hypothalamic tissues were frozen in liquid nitrogen
and ground mechanically on dry ice.
RNA extraction and gene expression analysis by
quantitative real-time PCR
Total RNA was isolated using TRIzol (Invitrogen) and
chloroform (Sigma) from N39 cells and ground brain
tissues. For qRT-PCR analysis, 3 μg of total RNA from
each sample was reverse-transcribed using a Reverse
Transcription System (Promega). Synthesized cDNA was
diluted 1:5 with water, and 2 μl was used as a tem-
plate for qRT-PCR. Primers were designed as follows:
Ins1 Forward, 5′-AGAGACCATCAGCAAGCAGGTCA-
3′; Ins1 Reverse, 5′-TACCAGGTGGGGACCACAAA
GA-3′; Ins2 Forward, 5′-GTGACCTTCAGACCTTGG
CACTG-3′; Ins2 Reverse, 5′-AGGCTGGGTAGTGGT
GGGTCTAG-3′; NeuroD1 Forward, 5′-TGACCTTTC
CCATGCTGAAT-3′; NeuroD1 Reverse, 5′-AAGTGC
TAAGGCAACGCAAT-3′; GAPDH Forward, 5′-GTC
AATGAAGGGGTCGTTGATGG-3′; and GAPDH Reverse,
5′-TCGTCCCGTAGACAAAATGGTGA-3′. qRT-PCR was
performed according to the SYBR Green protocol (SYBR
Premix Ex Taq, TaKaRa) in a Bio-Rad CFX-96 machine. An-
nealing and extension were done at 63 °C.
Enzyme-linked immunosorbent assay
Culture medium from Wnt3a-treated N39 cells was col-
lected and filtered with a 0.22 μm syringe filter. Vivaspin 2
(2000 MWCO Hydrosart; Sartorius) was used to concen-
trate 3 mL of medium to 35 μL. Insulin concentrations in
concentrated media were measured by using an ELISA
kit, which detects only mature insulin, purchased from
ALPCO Diagnostics.
Immunoblot analysis
N39 cells were plated at a density of 1.0 × 105/mL in
6-well plates. After appropriate treatments, cells were
washed with ice-cold PBS and harvested in lysis buffer
(50 mM Tris-HCl, pH 7.4, 250 mM sucrose, 5 mM
sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, 1 %
Triton X-100, 0.1 mM benzamidine, 10 μg/mL leupeptin,
1 mM DTT, 0.5 mM PMSF, 50 mM NaF, 1X protease
inhibitor cocktail (Calbiochem), 1X phosphatase inhibitor
cocktail (Sigma). Protein was extracted from hypothalamic
tissues with the same lysis buffer. Lysates (20 μg total pro-
tein) were separated on 10 % SDS-polyacrylamide gels and
blotted onto polyvinylidene difluoride membranes for
40 min at 20 V in transfer buffer containing 25 mM Tris
base and 192 mM glycine. The membranes were blocked
with 5 % skim milk for 3 h and then incubated with
primary antibodies against non-phospho β-catenin (1:3000;
Cell Signaling), total β-catenin (1:3000; Cell Signaling),
NeuroD1 (1:3000; AbCam), or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (1:5000; Cell Signaling) at 4 °C
overnight. After three washes with Tris-buffered saline
with 0.1 % of Tween 20 (TBST), the membranes were
incubated with horseradish peroxidase–linked second-
ary antibody and washed with TBST three times and
visualized by SuperSignal West Pico Chemiluminescent
Substrate (Thermo) according to the manufacturer’s
procedure. The intensity of bands was quantified using
NIH ImageJ analysis software.
Immunofluorescence analysis
N39 cells were seeded on poly-L-lysine–coated coverslips.
After treatment with Wnt3a for 24 h, cells were washed
with PBS, fixed with 4 % paraformaldehyde and perme-
abilized in 0.2 % Triton X-100, 0.1 M glycine. The cells
were then washed with PBS, blocked with BSA containing
antibody diluent (Invitrogen) at room temperature (RT)
and incubated with antibodies against proinsulin (1:50;
R&D Systems), non-phospho β-catenin (1:500; Cell Signal-
ing), and NeuroD1 (1:200; Santa Cruz) at 4 °C. Coverslips
were incubated with secondary antibodies for 2 h at RT,
and Hoechst 33342 (Invitrogen) was used for nuclear
staining for 10 min at RT. ProLong Diamond Antifade
Mountant (Invitrogen) was used for mounting coverslips.
Each slide was analyzed with an LSM700 confocal micro-
scope (Carl Zeiss). Images were analyzed with ZEN2012
software (Carl Zeiss).
Preperation of lentiviral shRNAs
Five TRC Lentiviral Non-targeting shRNAs control
(#RHS6848) and mouse NeuroD1 shRNAs (81773-81777,
Dharmacon) were cloned into the pLKO.1 lentiviral vector.
The pMD2.G and psPAX2 vectors were used as an enve-
lope and packaging vector, respectively, to produce lenti-
virus in the Lenti-X 293 T cell line (Clontech). Transient
transfections were performed with TurboFect Transfection
Reagent (Thermo) according to the manufacturer’s proto-
col. Cell supernatants containing virus were collected 72 h
post-transfection and filtered through 0.45 μm syringe
filters. Lentiviral vectors were concentrated by
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ultracentrifugation at 40,000 × g for 90 min at 4 °C. Viral
pellets were suspended in PBS.
Statistical analysis
Data were analyzed with GraphPad Prism software (Graph-
Pad Software). Statistical analysis was performed using
unpaired t-test.
Additional file
Additional file 1: Supplemental Figure S1. Wnt3a induces NeoruD1
prior to upregulation of Ins2. N39 cells were treated with vehicle (PBS)
or Wnt3a (25 or 100 ng/mL) for 1.5, 3 and 4.5h, and the levels of NeoruD1
mRNA (A) and Ins2 mRNA (B) were measured by qRT-PCR and normalized
to the levels of GAPDH mRNA (n=9). Data are means + SEM. *p < 0.05, **
p < 0.01, *** p < 0.001 compared with vehicle control at each time point.
(JPG 976 kb)
Abbreviations
AgRP: agouti-related peptide; BDI: brain-derived insulin; DIO: diet-induced
obese; Fz: frizzled; GSK3: glycogen synthase kinase 3; IR: insulin receptor;
LRP: low density lipoprotein receptor-related protein; N39 cell: mouse
hypothalamic neuronal cell; NeuroD1: neurogenic differentiation 1;
NIRKO: neuron-specific insulin receptor knockout; ob/ob: leptin-deficient;
POMC: pro-opiomelanocortin; SF1: steroidogenic factor 1; TCF: T-cell factor.
Competing interests
The authors declare that they have no conflict of interests.
Authors’ contributions
JL and EKK conceived and designed the study, interpreted the results, and
wrote the manuscript. JL and KK planned and performed experiments and
analyzed the results. SWY discussed the study and wrote the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the National Research Foundation of South
Korea (Grant No. 2013M3C7A1056099 and 2012M3A9C6049935) and the
DGIST R&D Program of the Ministry of Science, Information and Communication
Technology, and Future Planning of South Korea (Grant No. 15-BD-0402).
Received: 10 December 2015 Accepted: 26 February 2016
References
1. Schechter R, Whitmire J, Holtzclaw L, George M, Harlow R, Devaskar SU.
Developmental regulation of insulin in the mammalian central nervous system.
Brain Res. 1992;582(1):27–37.
2. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. Role
of brain insulin receptor in control of body weight and reproduction.
Science. 2000;289(5487):2122–5.
3. Woods SC, Seeley RJ, Baskin DG, Schwartz MW. Insulin and the blood-brain
barrier. Curr Pharm Des. 2003;9(10):795–800.
4. Fisher SJ, Bruning JC, Lannon S, Kahn CR. Insulin signaling in the central
nervous system is critical for the normal sympathoadrenal response to
hypoglycemia. Diabetes. 2005;54(5):1447–51.
5. Ott ASR, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus
and the risk of dementia: the Rotterdam study. Neurology. 1999;53(9):1937–42.
6. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired
insulin and insulin-like growth factor expression and signaling mechanisms in
Alzheimer’s disease–is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63–80.
7. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, et al. Role for
neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad
Sci U S A. 2004;101(9):3100–5. doi:10.1073/pnas.0308724101.
8. Cohen E, Dillin A. The insulin paradox: aging, proteotoxicity and
neurodegeneration. Nat Rev Neurosci. 2008;9(10):759–67. doi:10.1038/nrn2474.
9. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C. Defects
in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease
indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging.
2010;31(2):224–43. doi:10.1016/j.neurobiolaging.2008.04.002.
10. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Deficient brain insulin signalling
pathway in Alzheimer’s disease and diabetes. J Pathol. 2011;225(1):54–62.
doi:10.1002/path.2912.
11. Margolis RU, Altszuler N. Insulin in the cerebrospinal fluid. Nature.
1967;215(5108):1375–6.
12. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the
blood-brain barrier: saturability at euglycemic doses of insulin. Peptides.
1997;18(9):1423–9.
13. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed
in the central nervous system of the rat. Nature. 1978;272(5656):827–9.
14. Madadi G, Dalvi PS, Belsham DD. Regulation of brain insulin mRNA by
glucose and glucagon-like peptide 1. Biochem Biophys Res Commun.
2008;376(4):694–9. doi:10.1016/j.bbrc.2008.09.054.
15. Mehran AE, Templeman NM, Brigidi GS, Lim GE, Chu KY, Hu X, et al.
Hyperinsulinemia drives diet-induced obesity independently of brain insulin
production. Cell Metab. 2012;16(6):723–37. doi:10.1016/j.cmet.2012.10.019.
16. Shiao MS, Liao BY, Long M, Yu HT. Adaptive evolution of the insulin two-gene
system in mouse. Genetics. 2008;178(3):1683–91. doi:10.1534/genetics.108.087023.
17. Young 3rd WS. Periventricular hypothalamic cells in the rat brain contain
insulin mRNA. Neuropeptides. 1986;8(2):93–7.
18. Devaskar SU, Singh BS, Carnaghi LR, Rajakumar PA, Giddings SJ. Insulin II gene
expression in rat central nervous system. Regul Pept. 1993;48(1-2):55–63.
19. Devaskar SU, Giddings SJ, Rajakumar PA, Carnaghi LR, Menon RK, Zahm DS.
Insulin gene expression and insulin synthesis in mammalian neuronal cells.
J Biol Chem. 1994;269(11):8445–54.
20. Singh BS, Rajakumar PA, Eves EM, Rosner MR, Wainer BH, Devaskar SU. Insulin
gene expression in immortalized rat hippocampal and pheochromocytoma-12
cell lines. Regul Pept. 1997;69(1):7–14.
21. Hrytsenko O, Wright Jr JR, Morrison CM, Pohajdak B. Insulin expression in
the brain and pituitary cells of tilapia (Oreochromis niloticus). Brain Res.
2007;1135(1):31–40. doi:10.1016/j.brainres.2006.12.009.
22. Gerozissis K. Brain insulin, energy and glucose homeostasis; genes,
environment and metabolic pathologies. Eur J Pharmacol. 2008;585(1):38–49.
doi:10.1016/j.ejphar.2008.01.050.
23. Molnar G, Farago N, Kocsis AK, Rozsa M, Lovas S, Boldog E, et al. GABAergic
neurogliaform cells represent local sources of insulin in the cerebral cortex.
J Neurosci. 2014;34(4):1133–7. doi:10.1523/JNEUROSCI.4082-13.2014.
24. Dorn A, Rinne A, Bernstein HG, Hahn HJ, Ziegler M. Insulin and C-peptide in
human brain neurons (insulin/C-peptide/brain peptides/
immunohistochemistry/radioimmunoassay). J Hirnforsch. 1983;24(5):495–9.
25. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S,
et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer’s
disease. J Neural Transm. 1998;105(4-5):423–38.
26. Lee SM, Tole S, Grove E, McMahon AP. A local Wnt-3a signal is
required for development of the mammalian hippocampus.
Development. 2000;127(3):457–67.
27. Galceran J, Miyashita-Lin EM, Devaney E, Rubenstein JL, Grosschedl R.
Hippocampus development and generation of dentate gyrus granule cells
is regulated by LEF1. Development. 2000;127(3):469–82.
28. Zhou CJ, Zhao C, Pleasure SJ. Wnt signaling mutants have decreased
dentate granule cell production and radial glial scaffolding abnormalities.
J Neurosci. 2004;24(1):121–6. doi:10.1523/JNEUROSCI.4071-03.2004.
29. Logan CY, Nusse R. The Wnt signaling pathway in development and
disease. Annu Rev Cell Dev Biol. 2004;20:781–810. doi:10.1146/annurev.
cellbio.20.010403.113126.
30. Sander M, German MS. The beta cell transcription factors and development
of the pancreas. J Mol Med (Berl). 1997;75(5):327–40.
31. Heller RS, Klein T, Ling Z, Heimberg H, Katoh M, Madsen OD, et al.
Expression of Wnt, Frizzled, sFRP, and DKK genes in adult human pancreas.
Gene Expr. 2003;11(3-4):141–7.
32. Fujino T, Asaba H, Kang MJ, Ikeda Y, Sone H, Takada S, et al. Low-density
lipoprotein receptor-related protein 5 (LRP5) is essential for normal
cholesterol metabolism and glucose-induced insulin secretion. Proc Natl
Acad Sci U S A. 2003;100(1):229–34. doi:10.1073/pnas.0133792100.
33. Papadopoulou S, Edlund H. Attenuated Wnt signaling perturbs
pancreatic growth but not pancreatic function. Diabetes.
2005;54(10):2844–51.
Lee et al. Molecular Brain  (2016) 9:24 Page 11 of 12
34. Wells JM, Esni F, Boivin GP, Aronow BJ, Stuart W, Combs C, et al. Wnt/β-
catenin signaling is required for development of the exocrine pancreas.
BMC Dev Biol. 2007;7(1):4.
35. Kuwabara T, Kagalwala MN, Onuma Y, Ito Y, Warashina M, Terashima K, et al.
Insulin biosynthesis in neuronal progenitors derived from adult
hippocampus and the olfactory bulb. EMBO Mol Med. 2011;3(12):742–54.
doi:10.1002/emmm.201100177.
36. Schinner S, Ulgen F, Papewalis C, Schott M, Woelk A, Vidal-Puig A, et al.
Regulation of insulin secretion, glucokinase gene transcription and beta cell
proliferation by adipocyte-derived Wnt signalling molecules. Diabetologia.
2008;51(1):147–54. doi:10.1007/s00125-007-0848-0.
37. Patel S, Doble B, Woodgett JR. Glycogen synthase kinase-3 in insulin and Wnt
signalling: a double-edged sword? Biochem Soc Trans. 2004;32(Pt 5):803–8.
doi:10.1042/BST0320803.
38. Welters HJ, Kulkarni RN. Wnt signaling: relevance to beta-cell
biology and diabetes. Trends Endocrinol Metab. 2008;19(10):349–55.
doi:10.1016/j.tem.2008.08.004.
39. Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X, et al. Wnt
signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci
U S A. 2007;104(15):6247–52. doi:10.1073/pnas.0701509104.
40. Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan AB,
et al. Mapping Wnt/beta-catenin signaling during mouse development
and in colorectal tumors. Proc Natl Acad Sci U S A. 2003;100(6):3299–304.
doi:10.1073/pnas.0434590100.
41. Wang X, Kopinke D, Lin J, McPherson AD, Duncan RN, Otsuna H, et al. Wnt
signaling regulates postembryonic hypothalamic progenitor differentiation.
Dev Cell. 2012;23(3):624–36. doi:10.1016/j.devcel.2012.07.012.
42. Kokoeva MV, Yin H, Flier JS. Neurogenesis in the hypothalamus of adult
mice: potential role in energy balance. Science. 2005;310(5748):679–83.
doi:10.1126/science.1115360.
43. Pierce AA, Xu AW. De novo neurogenesis in adult hypothalamus as
a compensatory mechanism to regulate energy balance. J Neurosci.
2010;30(2):723–30. doi:10.1523/JNEUROSCI.2479-09.2010.
44. Benzler J, Ganjam GK, Kruger M, Pinkenburg O, Kutschke M, Stohr S, et al.
Hypothalamic glycogen synthase kinase 3beta has a central role in the regulation
of food intake and glucose metabolism. Biochem J. 2012;447(1):175–84.
doi:10.1042/BJ20120834.
45. Benzler J, Andrews ZB, Pracht C, Stohr S, Shepherd PR, Grattan DR, et al.
Hypothalamic WNT signalling is impaired during obesity and reinstated
by leptin treatment in male mice. Endocrinology. 2013;154(12):4737–45.
doi:10.1210/en.2013-1746.
46. Fernandez AM, Torres-Aleman I. The many faces of insulin-like peptide signalling
in the brain. Nat Rev Neurosci. 2012;13(4):225–39. doi:10.1038/nrn3209.
47. Gui S, Yuan G, Wang L, Zhou L, Xue Y, Yu Y, et al. Wnt3a regulates
proliferation, apoptosis and function of pancreatic NIT-1 beta cells via
activation of IRS2/PI3K signaling. J Cell Biochem. 2013;114(7):1488–97.
doi:10.1002/jcb.24490.
48. Staal FJ, Noort Mv M, Strous GJ, Clevers HC. Wnt signals are transmitted through
N-terminally dephosphorylated beta-catenin. EMBO Rep. 2002;3(1):63–8.
doi:10.1093/embo-reports/kvf002.
49. Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, et al. Wnt
signaling through inhibition of beta-catenin degradation in an intact Axin1
complex. Cell. 2012;149(6):1245–56. doi:10.1016/j.cell.2012.05.002.
50. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost
M, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins.
Chem Biol. 2003;10(12):1255–66.
51. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of
pluripotency in human and mouse embryonic stem cells through activation
of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med.
2004;10(1):55–63. doi:10.1038/nm979.
52. Sharma A, Moore M, Marcora E, Lee JE, Qiu Y, Samaras S, et al. The
NeuroD1/BETA2 sequences essential for insulin gene transcription colocalize
with those necessary for neurogenesis and p300/CREB binding protein
binding. Mol Cell Biol. 1999;19(1):704–13.
53. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is
required for inhibition of glucose production. Nat Med. 2002;8(12):1376–82.
doi:10.1038/nm798.
54. Porte Jr D, Baskin DG, Schwartz MW. Insulin signaling in the central nervous
system: a critical role in metabolic homeostasis and disease from C. elegans
to humans. Diabetes. 2005;54(5):1264–76.
55. Kuwabara T, Hsieh J, Muotri A, Yeo G, Warashina M, Lie DC, et al.
Wnt-mediated activation of NeuroD1 and retro-elements during adult
neurogenesis. Nat Neurosci. 2009;12(9):1097–105. doi:10.1038/nn.2360.
56. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of
glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature.
1995;378(6559):785–9. doi:10.1038/378785a0.
57. Srivastava AK, Pandey SK. Potential mechanism(s) involved in the regulation
of glycogen synthesis by insulin. Mol Cell Biochem. 1998;182(1-2):135–41.
58. Lee JE. Basic helix-loop-helix genes in neural development. Curr Opin
Neurobiol. 1997;7(1):13–20.
59. Crews ST, Fan CM. Remembrance of things PAS: regulation of development
by bHLH-PAS proteins. Curr Opin Genet Dev. 1999;9(5):580–7.
60. Mutoh H, Fung BP, Naya FJ, Tsai MJ, Nishitani J, Leiter AB. The basic helix-
loop-helix transcription factor BETA2/NeuroD is expressed in mammalian
enteroendocrine cells and activates secretin gene expression. Proc Natl
Acad Sci U S A. 1997;94(8):3560–4.
61. Khoo S, Griffen SC, Xia Y, Baer RJ, German MS, Cobb MH. Regulation of
insulin gene transcription by ERK1 and ERK2 in pancreatic beta cells. J Biol
Chem. 2003;278(35):32969–77. doi:10.1074/jbc.M301198200.
62. Petersen HV, Jensen JN, Stein R, Serup P. Glucose induced MAPK signalling
influences NeuroD1-mediated activation and nuclear localization. FEBS Lett.
2002;528(1-3):241–5.
63. Konner AC, Janoschek R, Plum L, Jordan SD, Rother E, Ma X, et al. Insulin action
in AgRP-expressing neurons is required for suppression of hepatic glucose
production. Cell Metab. 2007;5(6):438–49. doi:10.1016/j.cmet.2007.05.004.
64. Klockener T, Hess S, Belgardt BF, Paeger L, Verhagen LA, Husch A, et al.
High-fat feeding promotes obesity via insulin receptor/PI3K-dependent
inhibition of SF-1 VMH neurons. Nat Neurosci. 2011;14(7):911–8.
doi:10.1038/nn.2847.
65. Kim EK, Miller I, Aja S, Landree LE, Pinn M, McFadden J, et al. C75, a fatty acid
synthase inhibitor, reduces food intake via hypothalamic AMP-activated
protein kinase. J Biol Chem. 2004;279(19):19970–6. doi:10.1074/jbc.M402165200.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lee et al. Molecular Brain  (2016) 9:24 Page 12 of 12
